Novartis is now responsible for worldwide development ... to treat heart failure, and diabetes drug Galvus (vildagliptin) through its cardio-metabolic division, and is looking to expand its ...

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...